Immunohistochemical Analysis of Prognostic Protein Markers for Primary Localized Clear Cell Renal Cell Carcinoma

2013 ◽  
Vol 31 (1) ◽  
pp. 51-59 ◽  
Author(s):  
Thomas Weber ◽  
Matthias Meinhardt ◽  
Stefan Zastrow ◽  
Andreas Wienke ◽  
Susanne Fuessel ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Immunohistochemical Analysis ◽  
Protein Markers ◽  
Cell Renal Cell Carcinoma

scholarly journals Neo-Fs Index: A Novel Immunohistochemical Biomarker Panel Predicts Survival and Response to Anti-Angiogenetic Agents in Clear Cell Renal Cell Carcinoma

Cancers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1199
Author(s):  
Jisup Kim ◽  
Jee-Young Park ◽  
Su-Jin Shin ◽  
Beom Jin Lim ◽  
Heounjeong Go
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Plasmacytoid Dendritic Cell ◽  
Cytolytic Activity ◽  
Immune Gene ◽  
Protein Markers ◽  
Cell Renal Cell Carcinoma ◽  
Frameshift Indels

Background: Frameshift indels have emerged as a predictor of immunotherapy response but were not evaluated yet to predict anti-angiogenetic agent (AAA) response or prognosis in clear cell renal cell carcinoma (ccRCC). Methods: Here, to develop biomarkers that predict survival and response to AAA, we evaluated the immunohistochemical expression of proteins whose genes frequently harbor frameshift indels in 638 ccRCC patients and correlated the individual and integrated markers with prognosis and AAA response. The mutational landscape was evaluated using targeted next-generation sequencing in 12 patients concerning protein markers. Immune gene signatures were retrieved from TCGA RNA seq data. Results: Five proteins (APC, NOTCH1, ARID1A, EYS, and filamin A) were independent adverse prognosticators and were incorporated into the Neo-fs index. Better overall, disease-specific and recurrence-free survival were observed with high Neo-fs index in univariate and multivariate survival analyses. Better AAA responses were observed with a high Neo-fs index, which reflected increased MHC class I, CD8+ T cell, cytolytic activity, and plasmacytoid dendritic cell signatures and decreased type II-IFN response signatures, as well as greater single-nucleotide variant (SNV) and indel counts. Conclusions: Neo-fs index, reflecting antitumor immune signature and more SNVs. and indels, is a powerful predictor of survival and AAA response in ccRCC.

Low-Grade Clear Cell Renal Cell Carcinoma Mimicking Hemangioma of the Kidney: A Series of 4 Cases

2013 ◽  
Vol 137 (2) ◽  
pp. 251-254 ◽  
Author(s):  
Oleksandr N. Kryvenko ◽  
Leonardo Roquero ◽  
Nilesh S. Gupta ◽  
Min W. Lee ◽  
Jonathan I. Epstein
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Immunohistochemical Analysis ◽  
Low Grade ◽  
Renal Tubules ◽  
Cell Renal Cell Carcinoma ◽  
Vascular Neoplasm ◽  
Diagnostic Criterion

Context.— Clear cell renal cell carcinoma (CCRCC) has a rich, sinusoid-like vascularity frequently used as a diagnostic criterion. CCRCC with predominantly vascular architecture has not been described. Objective.— To describe 4 unusual CCRCC cases, primarily presenting with hemangioma-like morphologic pattern. Design.— Clinicopathologic and selected immunohistochemical analysis of 4 cases of CCRCC mimicking hemangioma. Results.— Cases were seen in 1 woman and 3 men (average age, 48.8 years; range, 40–66 years). Grossly, tumors were red-brown (3 of 4) with scant bright-yellow foci in 1. The average tumor size was 4 cm (range, 2.5–5.5 cm). Microscopically, all were composed of varying proportions of a rich, arborizing, sinusoid-like vasculature with focal hobnail appearance of endothelial cells. Entrapment of renal tubules between blood vessels was seen at the periphery of the tumors. This morphology was reminiscent of anastomosing hemangioma. Isolated tumor cells resembling lymphocytes with clear halos were sparsely interspersed between vessels. Cytokeratin immunostain confirmed the diagnosis of CCRCC. Conclusion.— Extensive sampling and immunohistochemical workup of what is deemed to be a benign vascular neoplasm of the kidney is needed to rule out the presence of individual carcinoma cells or small viable carcinoma cell clusters.

scholarly journals Recent advances in the systemic management of non-clear cell renal cell carcinoma: a review article

2020 ◽  
Vol 7 (9) ◽  
pp. 1446
Author(s):  
Soumish Sengupta ◽  
Supriya Basu ◽  
Kadambari Ghosh
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Mtor Inhibitors ◽  
Immunohistochemical Analysis ◽  
Cell Renal Cell Carcinoma ◽  
Drug Of Choice ◽  
Platinum Based Chemotherapy

Non-clear cell renal cell carcinoma (nccRCC) is not as common as clear cell renal cell carcinoma (ccRcc). But then it is not uncommon in regular urological practice. It usually carries a grave prognosis. Authors need to converse ourselves with National comprehensive cancer network (NCCN) categories for evidence and we need to converse as well with NCCN categories for preferences. ‘Preferred intervention’ is based on superior efficacy, safety and evidence and when appropriate, affordability. ‘Other recommended interventions’ are somewhat less efficacious, more toxic, or based on less mature data or significantly less affordable for similar outcomes. ‘Useful in certain circumstances’ are interventions that may be used for a selected patient population. Clinical trials for targeted agents are mainly directed at ccRCC because of its high prevalence. According to the NCCN panel, enrolment in clinical trials is the preferred strategy for nccRCC. Outcomes of patients with nccRCC have improved with the introduction of targeted therapy. Precise pathological diagnosis of the types of nccRCC by immunohistochemical analysis is mandatory. This enables specific treatments for individual nccRCC. Currently TKIs are the drug of choice (both first and second line) for metastatic papillary RCC. Both TKIs and mTOR inhibitors are effective against chromophobe RCC. Platinum based chemotherapy should be used for metastatic CDC. Further evidence is required for management of nccRCC. 

Immunohistochemical Analysis with Multiple Antibodies in Search of Prognostic Markers for Clear Cell Renal Cell Carcinoma

Urology ◽  
2007 ◽  
Vol 69 (5) ◽  
pp. 843-848 ◽  
Author(s):  
Nguyen Ba Phuoc ◽  
Hidetoshi Ehara ◽  
Takahiro Gotoh ◽  
Masahiro Nakano ◽  
Shigeaki Yokoi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Prognostic Markers ◽  
Clear Cell ◽  
Immunohistochemical Analysis ◽  
Cell Renal Cell Carcinoma

scholarly journals Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Florent Petitprez ◽  
Mira Ayadi ◽  
Aurélien de Reyniès ◽  
Wolf H. Fridman ◽  
Catherine Sautès-Fridman ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clinical Utility ◽  
Prognostic Markers ◽  
Clear Cell ◽  
Evidence Synthesis ◽  
Protein Markers ◽  
Cell Renal Cell Carcinoma ◽  
Pubmed Database

Context: The number of prognostic markers for clear cell renal cell carcinoma (ccRCC) has been increasing regularly over the last 15 years, without being integrated and compared.Objective: Our goal was to perform a review of prognostic markers for ccRCC to lay the ground for their use in the clinics.Evidence Acquisition: PubMed database was searched to identify RNA and protein markers whose expression level was reported as associated with survival of ccRCC patients. Relevant studies were selected through cross-reading by two readers.Evidence Synthesis: We selected 249 studies reporting an association with prognostic of either single markers or multiple-marker models. Altogether, these studies were based on a total of 341 distinct markers and 13 multiple-marker models. Twenty percent of these markers were involved in four biological pathways altered in ccRCC: cell cycle, angiogenesis, hypoxia, and immune response. The main genes (VHL, PBRM1, BAP1, and SETD2) involved in ccRCC carcinogenesis are not the most relevant for assessing survival.Conclusion: Among single markers, the most validated markers were KI67, BIRC5, TP53, CXCR4, and CA9. Of the multiple-marker models, the most famous model, ClearCode34, has been highly validated on several independent datasets, but its clinical utility has not yet been investigated.Patient Summary: Over the years, the prognosis studies have evolved from single markers to multiple-marker models. Our review highlights the highly validated prognostic markers and multiple-marker models and discusses their clinical utility for better therapeutic care.

638: Macroscopic Tumor Necrosis is a Prognostic Indicator for Non-Metastatic Clear Cell Renal Cell Carcinoma

2007 ◽  
Vol 177 (4S) ◽  
pp. 214-214
Author(s):  
Sung Kyu Hong ◽  
Byung Kyu Han ◽  
In Ho Chang ◽  
June Hyun Han ◽  
Ji Hyung Yu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Necrosis ◽  
Clear Cell ◽  
Prognostic Indicator ◽  
Cell Renal Cell Carcinoma ◽  
Macroscopic Tumor

Rare localization of renal cell carcinoma metastases in the paranasal sinuses and breast: a case report

2019 ◽  
Vol 22 (6) ◽  
pp. 13-22
Author(s):  
E. V. Kryaneva ◽  
N. A. Rubtsova ◽  
A. V. Levshakova ◽  
A. I. Khalimon ◽  
A. V. Leontyev ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Paranasal Sinuses ◽  
Renal Cell ◽  
Clinical Case ◽  
Clear Cell ◽  
Malignant Tumors ◽  
Metastatic Potential ◽  
Cell Renal Cell Carcinoma ◽  
Metastatic Lesions

This article presents a clinical case demonsratinga high metastatic potential of clear cell renal cell carcinoma combined with atypical metastases to breast and paranasal sinuses. The prevalence of metastatic lesions to the breast and paranasal sinuses in various malignant tumors depending on their morphological forms is analyzed. The authors present an analysis of data published for the last 30 years. The optimal diagnostic algorithms to detect the progression of renal cell carcinoma and to evaluate the effectiveness of the treatment are considered.

Sign in / Sign up

Export Citation Format

Share Document